Gonadotropin-Releasing Hormone Agonist Treatment in Postmenopausal Women with Hyperandrogenism of Ovarian Origin

被引:30
|
作者
Vollaard, Esther S. [1 ]
van Beek, Andre P. [2 ]
Verburg, Frederik A. J. [2 ]
Roos, Annemieke [3 ]
Land, Jolande A. [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Obstet & Gynecol, NL-9700 RB Groningen, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Endocrinol, NL-9700 RB Groningen, Netherlands
[3] Twenteborg Hosp, Dept Internal Med Endocrinol, NL-7600 SZ Almelo, Netherlands
来源
关键词
CELL TUMOR; RARE CAUSE; HYPERTHECOSIS; VIRILIZATION; WOMAN;
D O I
10.1210/jc.2010-1991
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: The most frequent cause of virilization in postmenopausal women is excessive androgen production of ovarian origin. Bilateral oophorectomy is usually performed, even in cases of benign tumors or hyperthecosis. This is the first report of a case series of long-term GnRH-agonist treatment of hyperandrogenism in postmenopausal women. Objective: We present three women with postmenopausal hyperandrogenism of ovarian origin who were treated with GnRH agonists. Patients: We describe three cases of postmenopausal women with virilization and hyperandrogenism of presumed ovarian origin, all with slight enlargement of the ovaries but without visualization of a tumor, who had long-term treatment with GnRH agonists. No histological diagnosis was available, and therefore all patients received careful follow-up, including periodic testing of androgen levels and ovarian imaging by computed tomography scans. The three patients responded in different ways to treatment with GnRH agonists. Conclusions: Long-term GnRH agonist treatment is an acceptable choice for treatment of postmenopausal hyperandrogenism in patients where ovarian origin of androgen excess is ascertained, and especially in those patients who have an increased risk for surgery due to comorbidities or who are unwilling to undergo bilateral oophorectomy. (J Clin Endocrinol Metab 96: 1197-1201, 2011)
引用
收藏
页码:1197 / 1201
页数:5
相关论文
共 50 条
  • [41] Model of gonadotropin-releasing hormone and gonadotropin-releasing hormone complex
    Wiwanitkit, Viroj
    [J]. SEXUALITY AND DISABILITY, 2006, 24 (03) : 175 - 178
  • [42] Decrease in gonadotropin-releasing hormone (GnRH) pulse frequency with aging in postmenopausal women
    Hall, JE
    Lavoie, HB
    Marsh, EE
    Martin, KA
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (05): : 1794 - 1800
  • [43] Model of gonadotropin-releasing hormone and gonadotropin-releasing hormone complex
    Viroj Wiwanitkit
    [J]. Sexuality and Disability, 2006, 24 : 175 - 178
  • [44] Gonadotropin-releasing hormone agonist induces downregulation of tensin 1 in women with endometriosis
    Rahmawati, Endah
    Yang, Wei-Chung V.
    Lei, Yen-Ping
    Maurya, Pawan K.
    Chen, Huei-Wen
    Tzeng, Chii-Ruey
    [J]. ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2019, 98 (02) : 222 - 231
  • [45] Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls
    Arani, Kobra Shiasi
    Heidari, Fatemeh
    [J]. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2015, 13 (03)
  • [46] Pulsatile gonadotropin-releasing hormone treatment
    Strowitzki T.
    [J]. Gynäkologische Endokrinologie, 2016, 14 (4) : 245 - 248
  • [47] INTRANASAL GONADOTROPIN-RELEASING HORMONE AGONIST AS A CONTRACEPTIVE AGENT
    BERGQUIST, C
    NILLIUS, SJ
    WIDE, L
    [J]. LANCET, 1979, 2 (8136): : 215 - 217
  • [48] Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome
    Kol, S
    [J]. FERTILITY AND STERILITY, 2004, 81 (01) : 1 - 5
  • [49] Effect of ovarian suppression with gonadotropin-releasing hormone agonist on glucose disposal and insulin secretion
    Toth, Michael J.
    Cooper, Brian C.
    Pratley, Richard E.
    Mari, Andrea
    Matthews, Dwight E.
    Casson, Peter R.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2008, 294 (06): : E1035 - E1045
  • [50] Utilization of gonadotropin-releasing hormone agonist products in adolescents
    Woods, Corinne
    Ho, Amy
    Dutcher, Sarah K.
    Ajao, Adebola
    Hawrusik, Rebecca
    Schoeplein, Ryan
    Moeny, David
    Huang, Ting-Ying
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 319 - 320